4,021 Shares in Insmed Incorporated (NASDAQ:INSM) Acquired by Fourth Dimension Wealth LLC

Fourth Dimension Wealth LLC purchased a new position in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 4,021 shares of the biopharmaceutical company's stock, valued at approximately $278,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of INSM. National Bank of Canada FI lifted its holdings in shares of Insmed by 9.7% during the fourth quarter. National Bank of Canada FI now owns 1,668 shares of the biopharmaceutical company's stock worth $115,000 after purchasing an additional 147 shares during the period. Abel Hall LLC lifted its stake in shares of Insmed by 4.7% in the 4th quarter. Abel Hall LLC now owns 3,333 shares of the biopharmaceutical company's stock worth $230,000 after acquiring an additional 151 shares during the period. Snowden Capital Advisors LLC lifted its stake in shares of Insmed by 2.5% in the 4th quarter. Snowden Capital Advisors LLC now owns 6,602 shares of the biopharmaceutical company's stock worth $456,000 after acquiring an additional 158 shares during the period. Steward Partners Investment Advisory LLC boosted its holdings in shares of Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 163 shares in the last quarter. Finally, M&T Bank Corp increased its stake in shares of Insmed by 5.6% during the fourth quarter. M&T Bank Corp now owns 3,146 shares of the biopharmaceutical company's stock worth $217,000 after acquiring an additional 166 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. UBS Group lowered their price objective on Insmed from $110.00 to $109.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Guggenheim restated a "buy" rating and issued a $101.00 price target on shares of Insmed in a research note on Tuesday, February 25th. HC Wainwright reaffirmed a "buy" rating and set a $90.00 price objective on shares of Insmed in a report on Monday, May 12th. Stifel Nicolaus cut their price objective on Insmed from $97.00 to $96.00 and set a "buy" rating for the company in a research report on Friday, February 21st. Finally, Royal Bank of Canada restated an "outperform" rating and set a $100.00 target price on shares of Insmed in a research report on Wednesday, March 19th. One analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $94.63.

Insider Buying and Selling at Insmed

In other news, insider Michael Alexander Smith sold 409 shares of the stock in a transaction that occurred on Wednesday, May 14th. The shares were sold at an average price of $65.61, for a total value of $26,834.49. Following the completion of the transaction, the insider now directly owns 91,794 shares in the company, valued at $6,022,604.34. This trade represents a 0.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO William Lewis sold 18,750 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $77.79, for a total value of $1,458,562.50. Following the sale, the chief executive officer now owns 334,186 shares in the company, valued at approximately $25,996,328.94. The trade was a 5.31% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 153,098 shares of company stock valued at $10,724,192 over the last ninety days. Corporate insiders own 3.00% of the company's stock.

Insmed Price Performance

Shares of INSM stock traded down $1.52 during trading hours on Wednesday, hitting $66.50. The company's stock had a trading volume of 806,291 shares, compared to its average volume of 2,328,606. Insmed Incorporated has a twelve month low of $44.51 and a twelve month high of $84.91. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The business has a fifty day moving average of $70.24 and a 200-day moving average of $72.99. The stock has a market cap of $12.11 billion, a price-to-earnings ratio of -11.89 and a beta of 0.84.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.36) by ($0.06). The firm had revenue of $92.82 million for the quarter, compared to analyst estimates of $91.63 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. Insmed's revenue for the quarter was up 22.9% on a year-over-year basis. During the same period in the prior year, the business earned ($1.06) earnings per share. As a group, equities research analysts anticipate that Insmed Incorporated will post -4.56 EPS for the current year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.